Fullgreen Sustainable Biomedicine Technology Co., Ltd. today announced the launch of its LNP and NLC drug nanocarrier CDMO services, providing pharmaceutical companies, biotech developers, generic drug manufacturers, and advanced formulation teams with an integrated platform for lipid-based drug delivery development. The new service focuses on Lipid Nanoparticles, or LNPs, and Nanostructured Lipid Carriers, or NLCs, to support the formulation of small-molecule drugs, poorly soluble compounds, lipophilic APIs, nucleic acid therapeutics, high-potency actives, and differentiated drug delivery products.

As the pharmaceutical industry continues to move beyond conventional active ingredient development, formulation technology has become a key driver of product differentiation, lifecycle management, and clinical value creation. Drug developers are increasingly seeking delivery systems that can improve solubility, enhance absorption, protect unstable molecules, modify release profiles, reduce formulation-related limitations, and create new intellectual property around existing or emerging therapeutic assets. Within this landscape, LNP and NLC technologies have become important platforms for next-generation drug delivery.

LNP technology is particularly relevant for nucleic acid therapeutics such as mRNA, siRNA, oligonucleotides, and other charged or sensitive biomolecules that require protection and efficient delivery. NLC technology, on the other hand, is well suited for lipophilic small molecules, poorly water-soluble drugs, dermatological products, transdermal systems, localized therapies, and controlled-release formulations. By adjusting lipid composition, surfactant systems, particle size, surface charge, crystallinity, drug-loading behavior, and release kinetics, these platforms can provide formulation flexibility that is difficult to achieve with traditional dosage forms.

Fullgreen’s LNP/NLC CDMO service is designed to go beyond simple formulation screening. The company provides an integrated development workflow that includes drug property assessment, nanocarrier platform selection, formulation design, process development, analytical method planning, stability evaluation, scale-up strategy, technology transfer, and CMC documentation support. Each project begins with a technical assessment of the API, including molecular weight, logP, pKa, solubility profile, melting point, crystallinity, charge characteristics, dose requirement, route of administration, target indication, and commercial development objective. Based on these parameters, Fullgreen helps customers determine whether LNP, NLC, lipid–drug complex, lipid–ion pairing, hybrid lipid nanoparticles, lipid microparticles, or other modified lipid-based systems are most appropriate.

At the early development stage, Fullgreen can support feasibility studies covering encapsulation efficiency, drug loading, particle size distribution, polydispersity index, zeta potential, precipitation risk, release profile, storage stability, freeze-drying feasibility, spray-drying feasibility, and formulation constraints associated with different administration routes. For highly hydrophobic or poorly soluble small molecules, NLC systems may help improve dispersion, dissolution behavior, physical stability, and sustained release potential. For nucleic acid or charged therapeutics, LNP systems may be designed through the careful optimization of ionizable lipids, helper lipids, cholesterol, PEG-lipids, aqueous phase composition, mixing conditions, and downstream purification methods.

A major strength of Fullgreen’s service model is the integration of formulation science with scalable manufacturing process development. The company can support laboratory-scale screening, pilot-scale process design, and continuous or semi-continuous nanomanufacturing workflows. Compared with conventional batch emulsification or manual mixing, continuous nanomanufacturing can improve lot-to-lot consistency, reduce scale-up risk, and provide tighter control over particle size, PDI, encapsulation efficiency, and residual solvent levels.

Quality control and analytical development are central to Fullgreen’s LNP/NLC CDMO offering. The company can help establish critical quality attribute testing strategies, including particle size, PDI, zeta potential, encapsulation efficiency, drug loading, free drug ratio, pH, osmolality, viscosity, appearance, microbial risk, endotoxin risk, residual solvent, lipid oxidation, API degradation, impurity profile, in vitro release behavior, and accelerated stability. Where appropriate, Fullgreen can apply Quality by Design principles and Design of Experiments approaches to identify critical material attributes and critical process parameters early in development. This allows customers to reduce uncertainty before entering larger-scale manufacturing, regulatory filing preparation, or partner technology transfer.

Fullgreen emphasizes that the true value of LNP/NLC CDMO services is not merely the ability to generate nanoparticles, but the ability to develop products that are scalable, measurable, stable, transferable, and commercially meaningful. For biotech and new drug developers, lipid nanocarriers may provide a path to improved therapeutic performance, dose reduction, enhanced tissue distribution, or differentiated intellectual property. For generic pharmaceutical companies, LNP and NLC platforms may support the development of value-added medicines, 505(b)(2)-type products, topical therapies, transdermal systems, controlled-release formulations, and high-barrier generic products. For API manufacturers and formulation companies, lipid nanocarriers may create a higher-value bridge between active ingredients and finished dosage forms.

The company also sees significant opportunities in repurposing and lifecycle extension of existing drugs. Many approved APIs face limitations related to poor solubility, low bioavailability, local irritation, short duration of action, food effects, formulation instability, or inadequate tissue exposure. Through NLC or LNP-based formulation redesign, these molecules may be repositioned into new dosage forms, new administration routes, or improved therapeutic profiles. Such strategies can be particularly valuable for dermatology, oncology support care, pain management, cardiovascular medicine, metabolic diseases, central nervous system applications, and localized delivery products.

In addition to formulation and process services, Fullgreen can support customers in building technical packages for partnering, licensing, investor communication, and regulatory-oriented development planning. These packages may include formulation rationale, excipient selection logic, process flow diagrams, preliminary specifications, stability study design, analytical testing plans, risk assessment, scale-up considerations, and development roadmaps. This helps customers communicate the value of their nanocarrier products more effectively to pharmaceutical partners, investors, and downstream manufacturing organizations.

Looking ahead, Fullgreen Sustainable Biomedicine aims to build a modular and platform-based CDMO service model centered on LNP, NLC, lipid material design, continuous nanomanufacturing, PAT-based process monitoring, and CMC-oriented development. By combining lipid formulation expertise with scalable process engineering and quality system thinking, Fullgreen seeks to become a distinctive drug delivery technology partner in Asia and global pharmaceutical markets. The company’s mission is to help promising drug candidates overcome solubility, absorption, stability, delivery, and formulation differentiation challenges through practical, scalable, and commercially relevant nanocarrier solutions.

About Fullgreen Sustainable Biomedicine Technology Co., Ltd.
Fullgreen Sustainable Biomedicine Technology Co., Ltd. focuses on the integrated development of lipid nanocarriers, continuous manufacturing, biomedical materials, cosmetic science, and pharmaceutical formulation technologies. Its service scope includes LNP/NLC formulation design, continuous API process development, high-value intermediates, nanocarrier delivery systems, analytical development, and technology transfer support. Fullgreen is committed to building efficient, scalable, verifiable, and sustainable technology platforms to help customers advance next-generation biomedical and pharmaceutical products.